Guest: Putao Cen, MD <br>


  <p>Here to give us a breakdown of what the latest clinical trials are saying about anti-EGFR therapies in left versus right-sided colorectal cancer tumors is Dr. Putao Cen, Associate Professor of Medical Oncology at the University of Texas Health Science Center McGovern Medical School.</p>

Guest: Putao Cen, MD Here to give us a breakdown of what the latest clinical trials are saying about anti-EGFR therapies in left versus right-sided colorectal cancer tumors is Dr. Putao Cen, Associate Professor of Medical Oncology at the University of Texas Health Science Center McGovern Medical School.

Comparing Anti-EGFR in Left vs. Right-Sided Colorectal Cancer Tumors: Survival Trends from the Latest Clinical Trials

Between 50 and 60 percent of patients diagnosed with colorectal cancer will develop metastases during the course of their disease, spreading to the lungs, liver, or other secondary location.
To help physicians tackle this very real threat facing their patients, Conversations on Colorectal Cancer focuses on the current guidelines and therapeutic landscape for metastatic colorectal cancer (mCRC).
This non-certified educational series is sponsored by Lilly. Content for this series is produced and controlled by ReachMD. This series is intended for healthcare professionals only.
 
 Sponsored by

Medicine

Between 50 and 60 percent of patients diagnosed with colorectal cancer will develop metastases during the course of their disease, spreading to the lungs, liver, or other secondary location. To help physicians tackle this very real threat facing their patients, Conversations on Colorectal Cancer focuses on the current guidelines and therapeutic landscape for metastatic colorectal cancer (mCRC). This non-certified educational series is sponsored by Lilly. Content for this series is produced and controlled by ReachMD. This series is intended for healthcare professionals only. Sponsored by

Between 50 and 60 percent of patients diagnosed with colorectal cancer will develop metastases during the course of their disease, spreading to the lungs, liver, or other secondary location.
To help physicians tackle this very real threat facing their patients, Conversations on Colorectal Cancer focuses on the current guidelines and therapeutic landscape for metastatic colorectal cancer (mCRC).
This non-certified educational series is sponsored by Lilly. Content for this series is produced and controlled by ReachMD. This series is intended for healthcare professionals only.
&nbsp;
&nbsp;Sponsored by

Share Comparing Anti-EGFR in Left vs. Right-Sided Colorectal Cancer Tumors: Survival Trends from the Latest Clinical Trials

Sign up to save your podcasts

Comparing Anti-EGFR in Left vs. Right-Sided Colorectal Cancer Tumors: Survival Trends from the Latest Clinical Trials

Comparing Anti-EGFR in Left vs. Right-Sided Colorectal Cancer Tumors: Survival Trends from the Latest Clinical Trials